文献速递前列腺癌

基因组检测后中危前列腺癌的主动监测选择与3年持续性

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-09-05

这项回顾性观察性队列研究纳入10个研究中心的3208例局限性中危前列腺癌患者,在诊断时接受Prolaris检测。Prolaris推荐主动监测(AS)的患者初始选择AS的比例约为推荐根治性治疗(DT)患者的2倍,3年AS持续性约为1.5倍(均p<0.0001)。

要点

  • Prolaris推荐AS者初始选择AS的比例约为推荐DT者的2倍(p<0.0001)。
  • Prolaris推荐AS者3年AS持续性约为推荐DT者的1.5倍(p<0.0001)。
  • 校正CAPRA或Gleason评分后,Prolaris治疗推荐仍是AS选择与持续性的显著预测因素。

核心结论

  • Prolaris为临床风险分层增加了显著信息,有助于治疗决策。
  • Prolaris推荐AS的中危前列腺癌患者更可能初始选择AS,且诊断后3年更可能继续AS。

研究设计与样本

  • 回顾性观察性队列研究,纳入10个研究中心的3208例患者。
  • 患者于2015年9月至2018年12月诊断时接受Prolaris检测。
  • Prolaris利用诊断活检计算的临床细胞周期风险联合评分,按Prolaris AS阈值分层:低于阈值推荐AS,高于阈值推荐DT。
  • 比较推荐AS与推荐DT患者的AS选择率和3年AS持续性。
  • 采用单变量和多变量逻辑回归模型及Cox比例风险模型分析。

主要发现

  • Prolaris推荐AS的患者初始选择AS的比例约为推荐DT患者的2倍(p<0.0001)。
  • Prolaris推荐AS的患者3年AS持续性约为推荐DT患者的1.5倍(p<0.0001)。
  • 校正CAPRA或Gleason评分后,Prolaris治疗推荐仍是初始AS选择和AS持续性的统计学显著预测因素。

关键数值与推荐

  • Prolaris AS阈值:低于阈值推荐AS,高于阈值推荐DT。
  • AS选择率:推荐AS组约为推荐DT组的2倍(p<0.0001)。
  • 3年AS持续性:推荐AS组约为推荐DT组的1.5倍(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genomic testing can add risk stratification information to clinicopathological features in prostate cancer, aiding in shared medical decision-making between the clinician and patient regarding whether active surveillance (AS) or definitive treatment (DT) is most appropriate. Here we examined initial AS selection and 3-year AS durability in patients diagnosed with localized intermediate-risk prostate cancer who underwent Prolaris testing before treatment decision-making. METHODS: This retrospective observational cohort study included 3208 patients from 10 study sites who underwent Prolaris testing at diagnosis from September 2015 to December 2018. Prolaris utilizes a combined clinical cell cycle risk score calculated at diagnostic biopsy to stratify patients by the Prolaris AS threshold (below threshold, patient recommended to AS or above threshold, patient recommended to DT). AS selection rates and 3-year AS durability were compared in patients recommended to AS or DT by Prolaris testing. Univariable and multivariable logistic regression models and Cox proportional hazard models were used with molecular and clinical variables as predictors of initial treatment decision and AS durability, respectively. RESULTS: AS selection was ~2 times higher in patients recommended to AS by Prolaris testing than in those recommended to DT (p < 0.0001). Three-year AS durability was ~1.5 times higher in patients recommended to AS by Prolaris testing than in those recommended to DT (p < 0.0001). Prolaris treatment recommendation remained a statistically significant predictor of initial AS selection and AS durability after accounting for CAPRA or Gleason scores. CONCLUSIONS: Prolaris added significant information to clinical risk stratification to aid in treatment decision making. Intermediate-risk prostate cancer patients who were recommended to AS by Prolaris were more likely to initially pursue AS and were more likely to remain on AS at 3 years post-diagnosis than patients recommended to DT.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Lenz L, Clegg W, Iliev D, et al. Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. Prostate Cancer Prostatic Dis. 2024. PMID: 39237680. doi:10.1038/s41391-024-00888-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。